|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.59 USD | +2.57% |
|
-1.25% | -50.70% |
| Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
| Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
10x Genomics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 618.73 million compared to USD 516.41 million a year ago. Net loss was USD 255.1 million compared to USD 166 million a year ago.
Basic loss per share from continuing operations was USD 2.18 compared to USD 1.46 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -50.70% | 3.3B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
10X GENOMICS, INC. 
